Table 2.
Univariate analysis of association between candidate risk factors and the time to CNS relapse.
| Univariate analysis |
||||
|---|---|---|---|---|
| Candidate prognostic factors | Comparison | HR | 95% CI | P value |
| Age group | >60 versus ≤60 | 1.418 | 0.361 to 5.565 | 0.617 |
| BMI | BMI ≥25 versus <25 | 0.896 | 0.230 to 3.486 | 0.874 |
| Tumor size | ≥50 mm versus <50 mm | 1.423 | 0.249 to 8.125 | 0.691 |
| Stage | Stage IIE versus I | 4.098 | 1.202 to 13.975 | 0.024 |
| Non-GCB | Positive versus negative | 0.638 | 0.141 to 2.882 | 0.560 |
| WBC count (109/l) | ≥5.5 versus <5.5 | 0.988 | 0.279 to 3.502 | 0.986 |
| NLR | ≥1.78 versus <1.78 | 0.690 | 0.201 to 2.369 | 0.556 |
| PLR | ≥130 versus <130 | 0.785 | 0.222 to 2.767 | 0.707 |
| LDH (IU/L) | ≥ UNL versus < UNL | 3.930 | 0.860 to 17.954 | 0.077 |
| HBsAg status | Positive versus negative | 1.849 | 0.442 to 7.729 | 0.400 |
| Stage-modified IPI score | 1-3 versus 0 | 11.582 | 1.716 to 78.189 | 0.012 |
| Treatment regimens | ||||
| Breast Surgery | Present versus absent | 0.759 | 0.186 to 3.098 | 0.701 |
| Intrathecal injection | Present versus absent | 2.410 | 0.626 to 9.277 | 0.201 |
| Rituximab exposure | Present versus absent | 1.094 | 0.243 to 4.914 | 0.906 |
| Radiation therapy | Present versus absent | 5.784 | 1.231 to 27.178 | 0.026 |
| Refractory disease | Present versus absent | 2.994 | 0.611 to 14.673 | 0.176 |
Note: BMI, body mass index; CNS, central nervous system; HBsAg, hepatitis B surface antigen; GCB, germinal center B-cell like. LDH, lactate dehydrogenase. CI, confidence intervals; NLR, neutrophil-lymphocyte Ratio; IPI, international prognostic index; PLR, platelet-lymphocyte ratio; UNL. Upper Normal Limit; WBC, white blood cell; HR, hazard ratio.